Treatment of diabetes in patients undergoing organ replacement is not often studied.Read More »
Susan received a phone call from her clinician's office recommending that she start using a pen for her insulin.
She had also been prescribed a GLP-1 receptor agonist and was to go to the pharmacy to pick them up.
She went and signed up for the long 'discourse' patients receive when they pick up new meds including questions such as whether or not the pharmacist had offered instructions and pages of small print. She, like many of our patients, signed the sheets and went on her own way without ever talking to a pharmacist or asking a question.
One diabetes drug showed superior results for A1C reduction and weight loss.Read More »
The EXSCEL trial may not have shown that once-weekly exenatide had cardiovascular benefits for patients with diabetes, but did show a benefit in some significant areas.Read More »
A recent exploratory analysis of the REWIND trial evaluated a potential additive benefit to using a once-weekly GLP-1 RA.Read More »
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?Read More »
How many years can semaglutide add to your life?Read More »
Cardiovascular events decline for patients using which antidiabetic medication?Read More »
Data from the REWIND trial suggest that dulaglutide has cardioprotective properties.Read More »
The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c.Read More »